Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Actemra in children and adolescents with adamantinomatous craniopharyngioma
NCT03970226Phase 1Active, not recruiting
- Sponsor
- University of Colorado Denver
- Start
- Sep 2019
- Primary completion
- May 2024
- Modality
- Antibody Conjugates, Recombinant Proteins and Enzymes, Engineered Antibody Formats
- Countries
- 1
01
Overview
Phase 1, open-label trial of tocilizumab in craniopharyngioma, sponsored by University of Colorado Denver. Primary endpoint: Presence of Tocilizumab and Metabolites. Started Sep 2019; status: active, not recruiting.
02
Drugs
tocilizumab
03
Conditions
craniopharyngioma
Beyond the preview
Go deeper on NCT03970226.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03970226.